@FierceBiotech: Still popular: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech
@JohnCFierce: Osiris exits stem cell business, sells unit to Mesoblast in $100M deal. News | Follow @JohnCFierce
@DamianFierce: In case you missed it, some thoughts on why med tech companies aren't riding the biotech IPO wave. Editor's Corner | Follow @DamianFierce
@EmilyMFierce: Compound halts neurodegeneration in mice. Story from FierceBiotech Research | Follow @EmilyMFierce
> Rexahn Pharmaceuticals ($RNN) has signed a deal to sell $5.3 million in securities through a direct offering, cash it'll use to develop the cancer drugs Archexin, RX-3117, and RX-5902. News
> Are this year's beneficiaries of the biotech IPO boom doomed to tank when investors' lock-up periods expire? OncoMed Pharmaceutials ($OMED) CEO Paul Hastings advises companies how to maintain value. Interview
> Bay Area biotech Neuraltus Pharmaceuticals is raising $30 million to fund a Phase II study of a treatment for Lou Gehrig's disease. More
@FierceMedDev: Biotronik unveils next-gen MRI-safe ICDs. ICYMI yesterday | Follow @FierceMedDev
@MarkHFierce: Quest Diagnostics warns that its Q3 numbers won't be meeting expectations. Blame reimbursement pressures, etc. More | Follow @MarkHFierce
@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce
> St. Jude Medical CEO knocks rival and regulatory climate, but also offers optimism. More
> Gov't shutdown halts FCC's wireless med tech certification. Item
> Bipartisan backing of device tax repeal threatened by gov't funding fight. Story
> German-U.S. team test intestinal tube implant to treat obesity. Article
Pharma News
@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma
@EricPFierce: Sanofi spent €39B on emerging markets deals over 4 years. It has 40 manufacturing sites in these countries. More | Follow @EricPFierce
@CarlyHFierce: Vivus and Auxilium sign marketing deal for ED drug Stendra in the U.S. and Canada. Article | Release | Follow @CarlyHFierce
> Fresenius punished distributor for selling its drug for executions. Report
> J&J, AstraZeneca take Zytiga to Japan. Article
> FDA signoff on Ranbaxy NJ plant may provide drugmaker relief. Story